For the quarter ending 2026-03-31, IDYA made $6,560K in revenue. -$101,300K in net income. Net profit margin of -1544.21%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration revenue | 6,560 | 10,876 | 207,834 | - |
| Research and development | 95,726 | 86,599 | 82,993 | 74,226 |
| General and administrative | 19,378 | 18,847 | 16,389 | 14,580 |
| Total operating expenses | 115,104 | 105,446 | 99,382 | 88,806 |
| Loss from operations | -108,544 | -94,570 | 108,452 | -88,806 |
| Interest income and other income, net | 10,005 | 11,297 | 10,792 | 11,315 |
| Net loss | -98,539 | -83,273 | 119,244 | -77,491 |
| Unrealized (losses) gains on marketable securities | -2,761 | 215 | 531 | -64 |
| Comprehensive loss | -101,300 | -83,058 | 119,775 | -77,555 |
| Basic EPS | -1.11 | -0.938 | 1.35 | -0.88 |
| Diluted EPS | -1.11 | -0.95 | 1.33 | -0.88 |
| Basic Average Shares | 88,699,754 | 88,585,639 | 88,526,781 | 88,472,197 |
| Diluted Average Shares | 88,699,754 | 87,421,542 | 89,690,878 | 88,472,197 |
IDEAYA Biosciences, Inc. (IDYA)
IDEAYA Biosciences, Inc. (IDYA)